About the Company
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FENC News
RTP firm inks licensing deal for European drug launch
A drugmaker in Research Triangle Park has landed more than $40 million in a licensing deal and could earn much more.
Norgine to commercialize Fennec Pharma’s Pedmarqsi in Europe, Australia & New Zealand
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, announced an exclusive licensing agreement under ...
Analysts Are Optimistic We'll See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
We feel now is a pretty good time to analyse Fennec Pharmaceuticals Inc.'s ( NASDAQ:FENC ) business as it appears ...
Fennec, Norgine Reach Licensing Deal To Commercialize Pedmarqsi In Europe, Australia, & New Zealand
(RTTNews) - Fennec Pharmaceuticals Inc. (FENC, FRX.TO), a commercial stage specialty pharmaceutical company, and Norgine, a European specialist pharmaceutical company, announced an exclusive licensing ...
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of ...
Fennec Pharmaceuticals Inc FENC
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price
Read about Fennec's (FENC) sales guidance that surpassed expectations, upcoming EU launch of PEDMARK®, revenue growth in the ...
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an ...
Fennec Pharmaceuticals Inc FENC
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Austra
Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved ...
Fennec Pharmaceuticals Inc. (FENC)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...